Policy on the Development and Use of Practice Guidelines
AASLD, recognizing the need to develop practice guidelines for liver diseases, has established a Practice Guidelines Committee. AASLD guidelines represent the official opinion of the Association, as reflected in the evidence based reviews and recommendations of the individuals involved in developing the guidelines.
Guidelines Development
The Practice Guidelines Committee is responsible for developing AASLD's guidelines.
Members of the Practice Guidelines Committee serve a term of three years and have a wide range of expertise, from transplantation to pediatrics to clinical virology.
The Practice Guidelines have been developed by AASLD and in some instances has collaborated with other societies. All guidelines have been posted within each of the six categories below:
For any questions concerning Practice Guidelines, contact AASLD.
1. Metabolic/Genetic/Autoimmune Liver Disease Guidelines
Practice guidelines on the diagnosis and management of chronic liver diseases resulting from metabolic and hereditary neurologic diseases that often lead to cirrhosis or unresolving inflammation of the liver.
2. Viral Hepatitis Guidelines
Practice guidelines on the diagnosis and management of patients with hepatitis B and C.
3. Portal Hypertension Guidelines
Practice guidelines on the management of patients with ascites, the most common complication of cirrhosis, and the use of transjugular intrahepatic portasystemic shunt in the treatment of recurrent bleeding from varices and cirrhotic ascites.
4. End Stage Liver Disease/Surgery Guidelines
Practice guidelines on the management of patients with liver cancer and the indications for liver transplantation.
5. Position Papers on Other Disorders
Position paper on the condition of rapid development of liver failure associated with altered mentation and coagulopathy in patients without previously recognized liver disease.
6. Related Societies
Practice guidelines available from related societies.
*Please note: AASLD is not responsible for the information housed on these websites.
2007 Platinum support of the practice guidelines PDA adaptation by Astellas Pharma U.S., Inc. and Bristol-Myers Squibb Company is gratefully acknowledged.